| Literature DB >> 35453574 |
Irina V Pronina1, Leonid A Uroshlev1,2, Alexey A Moskovtsev1,3, Danila M Zaichenko1, Elena A Filippova1, Marina V Fridman2, Alexey M Burdennyy1, Vitaly I Loginov1, Tatiana P Kazubskaya4, Nikolay E Kushlinskii4, Alexey A Dmitriev5, Eleonora A Braga1, Olga I Brovkina1,6.
Abstract
Ovarian cancer (OC) is one of the most common types of cancer among malignancies of the female reproductive system. This pathology is asymptomatic until advanced stages and has a poor prognosis. Our study aimed to search for lncRNA-miRNA-mRNA competing triplets that promote ovarian tumorigenesis. For this purpose, we analyzed tumor samples from the TCGA database and verified the results experimentally in a set of 46 paired samples of tumor and matched histologically unchanged ovarian tissues from OC patients. The list of RNAs selected in silico for experimental studies included 13 mRNAs, 10 lncRNAs, and 5 miRNAs related to epithelial-mesenchymal transition and angiogenesis. We evaluated the expression of these RNAs by qRT-PCR and assessed the correlation between levels of miRNAs, mRNAs, and lncRNAs. Sixteen significant triplets were revealed, in some of which, e.g., OIP5-AS1-miR-203a-c-MET and OIP5-AS1-miR-203a-ZEB2, both lncRNA and mRNA had sites for miR-203a direct binding. Transfection of the OVCAR-3 and SKOV-3 cell lines with the miR-203a mimic was used to confirm the novel links of miR-203a with ZEB2 and c-MET in OC. These connections suggest that the interactomes have the potential for diagnostics of metastasis at early onset.Entities:
Keywords: differentially expressed genes; interactome; lncRNA; mRNA; microRNA; noncoding RNA; ovarian cancer; primary tumors; triplets
Year: 2022 PMID: 35453574 PMCID: PMC9031843 DOI: 10.3390/biomedicines10040824
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Figure 1The most significant pathways in OC according to the gene set enrichment analysis (GSEA).
Characteristics of the selected RNAs.
| RNA | Chromosome (Position) * | Localization in a Cell ** | LogFC | LogFC |
|---|---|---|---|---|
|
| ||||
| MALAT1 | Chr11 (65,497,738–65,506,516) | Nucleus | 5.0 | 1.1 |
| MAFG-DT | Chr17 (81,927,829–81,930,753) | Extracellular space | 2.9 | 0.8 |
| OIP5-AS1 | Chr15 (41,282,697–41,313,338) | Nucleus | 5.0 | 3.3 |
| MLK7-AS1 | Chr2 (173,197,712–173,282,036) | No information | 1.5 | 2.5 |
| LINC00339 | Chr1 (22,025,191–22,031,224) | Extracellular space, | 1.5 | 2.5 |
| TUG1 | Chr22 (30,969,211–30,979,395) | Extracellular space, | 38.8 | 2.1 |
| UCA1 | Chr19 (15,828,947–15,836,321) | Extracellular space, | 1.6 | 1.4 |
| SNHG14 | Chr15 (24,823,608–25,419,462) | Nucleus | 2.3 | −1.1 |
| CCAT1 | Chr8 (127,207,382–127,219,268) | Nucleus | 11.6 | 1.3 |
| DSCAM-AS1 | Chr21 (40,383,083–40,385,358) | Extracellular space, | 27.7 | 1.4 |
|
| ||||
| miR-148a | Chr7 (25,949,919–25,949,986) | Extracellular space and vesicles | N/A | −4.0 |
| miR-191 | Chr3 (49,020,618–49,020,709) | Extracellular space and vesicles | N/A | −3.8 |
| miR-203a | Chr14 (104,117,405–104,117,514) | Nucleus | N/A | −2.1 |
| miR-124a | Chr8 (9,903,388–9,903,472) | Cytoplasm and | N/A | −3.4 |
| miR-375 | Chr2 (219,001,645–219,001,708) | Extracellular space | N/A | −2.5 |
|
| ||||
| AURKA | Chr20 (56,369,390–56,392,308) | Nucleus | 1.8 | 1.2 |
| BCL2 | Chr18 (63,123,346–63,320,280) | Nucleus | 3.2 | 1.8 |
| CDK4 | Chr12 (57,747,727–57,752,310) | Nucleus | 2.1 | 1.3 |
| c-MET | Chr7 (116,672,196–116,798,386) | Extracellular space | 3.2 | 1.6 |
| WNT4 | Chr1 (22,117,308–22,143,981) | Extracellular space | 2.7 | −1.6 |
| YAP1 | Chr11 (102,109,957–102,233,424) | Nucleus and cytosol | 2.2 | 2.0 |
| ZEB1 | Chr10 (31,318,417–31,529,804) | Nucleus and cytosol | 2.1 | 2.9 |
| ZEB2 | Chr2 (144,384,081–144,520,119) | Nucleus and cytosol | 1.7 | 1.1 |
| CCND1 | Chr11 (69,641,156–69,654,474) | Nucleus and cytosol | 3.2 | 1.5 |
| ADAM9 | Chr8 (38,996,767–39,105,261) | Extracellular space | 8.0 | 0.3 |
| SOX4 | Chr6 (21,593,751–21,598,619) | Nucleus | 1.8 | 1.2 |
| TGFB | Chr19 (41,330,323–41,353,922) | Extracellular space, | 1.8 | 0.9 |
| MAPK1 | Chr22 (21,759,657–21,867,680) | Extracellular space, | 1.9 | 0.9 |
LogFC—binary logarithm of expression level fold change (tumor vs. normal). * The genome coordinates are specified according to the hg38 genome assembly. ** The localization of the RNAs is included according to the UniProt database (https://www.uniprot.org/, accessed on 9 December 2021).
Figure 2Expression levels of 5 tumor-suppressive miRNAs in OC. p.adj < 0.05 for each miRNA.
Figure 3Expression levels of 10 lncRNAs in OC. p.adj < 0.05 for each lncRNA.
Figure 4Expression levels of 13 mRNAs in OC. p.adj < 0.05 for each mRNA.
Spearman’s correlation coefficients between expression levels for different pairs of RNAs.
| Type of RNA | ||
|---|---|---|
|
|
| |
| miR-148a | MAFG-DT | −0.37 |
| miR-203a | MALAT1 | −0.42 |
| OIP5-AS1 | −0.42 | |
| MLK7-AS1 | −0.41 | |
| LINC00339 | −0.39 | |
|
|
| |
| miR-148a | BCL2 | −0.44 |
| miR-203a | CDK4 | −0.54 |
| c-MET | −0.42 | |
| ZEB1 | −0.34 | |
| ZEB2 | −0.41 | |
| WNT4 | −0.41 | |
| YAP1 | −0.53 | |
|
|
| |
| MAFG-DT | BCL2 | 0.45 |
| MALAT1 | CDK4 | 0.52 |
| c-MET | 0.39 | |
| ZEB1 | 0.38 | |
| OIP5-AS1 | CDK4 | 0.53 |
| c-MET | 0.37 | |
| WNT4 | 0.56 | |
| YAP1 | 0.61 | |
| ZEB1 | 0.57 | |
| ZEB2 | 0.65 | |
| MLK7-AS1 | CDK4 | 0.40 |
| YAP1 | 0.51 | |
| ZEB2 | 0.49 | |
| LINC00339 | CDK4 | 0.53 |
| YAP1 | 0.55 | |
| ZEB1 | 0.43 | |
* p.adj < 0.05 for all Spearman’s correlation coefficients.
Figure 5The network between three types of RNAs validated in a set of paired OC samples.
Data on the possibility of miR-203 binding to the selected lncRNAs and mRNAs.
| RNA | Sequence (GRCh37/hg19) | Binding Site |
|---|---|---|
|
| ||
| MALAT1 | no binding site | - |
| OIP5-AS1 | chr15: 41,593,028–41,593,127 | 7-mer-m8 |
| MLK7-AS1 | chr2: 174,080,356–174,080,455 | 7-mer-m8 |
| LINC00339 | no binding site | - |
|
| ||
| CDK4 | no binding site | - |
| c-MET | chr7: 116,415,099–116,415,198 | 8-mer |
| WNT4 | no binding site | - |
| YAP1 | no binding site | - |
| ZEB1 | chr10: 31,817,289–31,817,388 | 7-mer-m8 |
| ZEB2 | chr2: 145,184,392–145,184,491 | 8-mer |
The data are presented according to TargetScan v.7.2 and DIANA-TarBase v.8.
Figure 6Relative expression levels of 5 mRNAs in OVCAR-3 and SKOV-3 cell lines transfected with the miR-203a mimic. p.adj < 0.05 for each mRNA, the results are based on three technical replicates.
Figure 7The workflow of bioinformatic analysis for identification of lncRNA–miRNA–mRNA triplets.
Clinical and histological characteristics of OC patients and tissue samples.
| Clinical Characteristics | N (%) | |
|---|---|---|
| Age, years | <40 | 7 (15) |
| 40–60 | 22 (48) | |
| >60 | 17 (37) | |
| Histological type | Borderline serous adenocarcinoma | 3 (6) |
| Serous adenocarcinoma | 33 (72) | |
| Endometrioid adenocarcinoma | 5 (12) | |
| Clear cell adenocarcinoma | 1 (2) | |
| Mixed epithelial tumors | 2 (4) | |
| Undifferentiated carcinoma | 2 (4) | |
| Stage | I | 12 (26) |
| II | 10 (22) | |
| III | 22 (48) | |
| IV | 2 (4) | |
| Primary tumor site and size | T1 | 12 (26) |
| T2 | 10 (22) | |
| T3 | 24 (52) | |
| Lymph node | Nx | 16 (34) |
| N0 | 30 (65) | |
| N1 | 10 (21) | |
| Peritoneal metastases | Absent | 32 (69) |
| Present | 14 (31) | |